Implantable electromagnetic pulsation type artificial heart blood pump

Abstract

The invention relates to the technical field of medical instruments, in particular to an implantable electromagnetic pulsation type artificial heart blood pump which comprises a pump body and an electromagnetic driving device, the pump body is implanted into a body when used, and a soft first diaphragm is arranged in the pump body; the periphery of the first diaphragm is connected with the inner cavity wall of the pump body so as to divide the inner cavity of the pump body into a first cavity and a second cavity which are mutually sealed and isolated, the first cavity is an artificial heart cavity, and an inlet and an outlet for sucking and discharging blood are formed in the artificial heart cavity respectively; electromagnetic force serves as driving force to drive the first diaphragm to move in a reciprocating mode, then the blood discharging function of the artificial heart cavity is achieved, no other mechanical moving parts exist in the artificial heart cavity, blood cannot be damaged, no excessive mechanical moving parts occupy space, the space utilization rate of the pump body is very high, and the size can be very small and exquisite; and the device can be implanted under a thoracoscope, is simple to operate and is easily accepted by doctors and patients.

Description

technical field [0001] The invention relates to the technical field of medical devices, in particular to an implantable electromagnetic pulse type artificial heart blood pump. Background technique [0002] Heart failure (heart failure) referred to as heart failure refers to the failure of the venous blood to fully discharge the heart due to the dysfunction of the systolic function and / or diastolic function of the heart, resulting in blood stasis in the venous system and insufficient blood perfusion in the arterial system, resulting in Cardiac circulatory disorder syndrome, which is characterized by pulmonary congestion and vena cava congestion. Heart failure is not an independent disease, but the end stage of the development of heart disease. The vast majority of heart failures begin with left heart failure, that is, the first manifestation is pulmonary circulation congestion. The two-year survival rate of heart failure drug treatment is about 80%, and the five-year surviv...

AI Technical Summary

Problems solved by technology

At present, intra-aortic balloon counterpulsation is effective for patients with heart failure with low cardiac output and cardiogenic shock, but the equipment is bulky and cannot be carried, so it is not suitable and inconvenient for long-term use

Most of the foreign artificial heart research focuses on imitating the heart structure, and it is necessary to replace and remove the patient's heart. Due to insufficient energy supply, although artificial hearts are also used clinically, the risk of death of patients is high, and the life span is very short. Finally, because of the short life span , many complications, not accepted by patients, and difficult to promote

Heart transplantation is often difficult to be widely implemented due to lack of donors, large surgical trauma, high cost, and high immune rejection

[0003] The Chinese invention patent with the patent number 201010174301.8 and the patent title "Implantable Magnetic Liquid Suspension Centrifugal Blood Pump" discloses a centrifugal blood pump to assist or replace the human heart to drain blood, but the rotating blades shear and damage blood cells , Blood leaks to the periphery of the suspension shaft, causing the shaft to stop, titanium alloy and blood compatibility, high price and difficult to popularize and use, etc.

Images